OBJECTIVES: To quantify patient preferences when making decisions as to whether to accept latent tuberculosis infection (LTBI) preventive treatment, using a discrete choice experiment (DCE). METHODS: A DCE survey was developed and administered to LTBI patients. Each patient was given 10 random choices along with two fixed choices to check consistency. Two hypothetical treatment options and one opt-out option were presented in each choice task. Latent class analysis was conducted to estimate preferences for six key treatment attributes. RESULTS: Among the 214 respondents, 194 (90.7%) who provided valid DCE responses and complete sociodemographic information were included. Results consistently suggested that respondents were averse to higher risk of active tuberculosis and side effects and longer treatment. A three-latent-class model with five covariates was chosen. Forty-seven percent of the respondents were assigned to class 1, 32% to class 2, and 21% to class 3. Although all six attributes were shown to significantly influence the respondents' treatment decision, the risk of active tuberculosis, chance of liver damage, and frequency of clinic visits were the most important ones. Significant preference heterogeneity was observed in two attributes: frequency of clinic visits (P < 0.01) and chance of liver damage developing (P < 0.01). Class 1 individuals were most likely to have children. Class 2 had the highest employment rate. Class 3 respondents tended to choose the opt-out option on DCE tasks and were more likely to be born outside Canada, have higher education, and be unemployed. CONCLUSION: Respondents consistently preferred preventive treatment with higher effectiveness, fewer side effects, and shorter length. Substantial preference heterogeneity existed among respondents.
OBJECTIVES: To quantify patient preferences when making decisions as to whether to accept latent tuberculosis infection (LTBI) preventive treatment, using a discrete choice experiment (DCE). METHODS: A DCE survey was developed and administered to LTBI patients. Each patient was given 10 random choices along with two fixed choices to check consistency. Two hypothetical treatment options and one opt-out option were presented in each choice task. Latent class analysis was conducted to estimate preferences for six key treatment attributes. RESULTS: Among the 214 respondents, 194 (90.7%) who provided valid DCE responses and complete sociodemographic information were included. Results consistently suggested that respondents were averse to higher risk of active tuberculosis and side effects and longer treatment. A three-latent-class model with five covariates was chosen. Forty-seven percent of the respondents were assigned to class 1, 32% to class 2, and 21% to class 3. Although all six attributes were shown to significantly influence the respondents' treatment decision, the risk of active tuberculosis, chance of liver damage, and frequency of clinic visits were the most important ones. Significant preference heterogeneity was observed in two attributes: frequency of clinic visits (P < 0.01) and chance of liver damage developing (P < 0.01). Class 1 individuals were most likely to have children. Class 2 had the highest employment rate. Class 3 respondents tended to choose the opt-out option on DCE tasks and were more likely to be born outside Canada, have higher education, and be unemployed. CONCLUSION: Respondents consistently preferred preventive treatment with higher effectiveness, fewer side effects, and shorter length. Substantial preference heterogeneity existed among respondents.
Authors: Liana Fraenkel; Joseph Lim; Guadalupe Garcia-Tsao; Valerie Reyna; Alexander Monto; John F P Bridges Journal: Patient Date: 2016-06 Impact factor: 3.481
Authors: Carlo A Marra; Stephanie Harvard; Maja Grubisic; Jessica Galo; Ann Clarke; Susan Elliott; Larry D Lynd Journal: Allergy Asthma Clin Immunol Date: 2017-04-04 Impact factor: 3.406
Authors: Courtney M Yuen; Ana K Millones; Jerome T Galea; Daniela Puma; Judith Jimenez; Leonid Lecca; Mercedes C Becerra; Salmaan Keshavjee Journal: BMC Public Health Date: 2021-01-11 Impact factor: 3.295
Authors: Rachel K Lim; Fred C Semitala; Elly Atuhumuza; Laban Sabiti; Jane Namakula-Katende; Winnie R Muyindike; Moses R Kamya; David Dowdy; Adithya Cattamanchi Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240